Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment

Cancer Letters

Volumn 388, Issue , 2017, Pages 1-11

  Zhang, Hui Lu ^a   Wang, Ming Da ^b   Zhou, Xu ^b   Qin, Chen Jie ^b   Fu, Gong Bo ^b   Tang, Liang ^b,c   Wu, Han ^b   Huang, Shuai ^b   Zhao, Ling Hao ^b   Zeng, Min ^b   Liu, Jiao ^b   Cao, Dan ^b   Guo, Lin Na ^b   Wang, Hong Yang ^b,c   Yan, He Xin ^b,c   Liu, Jie ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c National Scientific Centre for Liver Cancer   (China)

Author keywords

Glucose uptake; GLUT1 3; IL 6 STAT3; Nutrition stress; Sorafenib; Tumor initiating cells

Indexed keywords

CD133 ANTIGEN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; INTERLEUKIN 6; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SORAFENIB; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; GLUCOSE; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE RESTRICTION; GLUCOSE TRANSPORT; GLUT1 GENE; GLUT2 GENE; GLUT3 GENE; GLUT4 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LIVER TUMOR INITIATING CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; CANCER STEM CELL; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; GLUCOSE; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 85003956473     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.11.023     Document Type: Article

References (57)

1. [1] Marrero, J.A., Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 22:3 (2006), 248–253.
2. [2] Bruix, J., Boix, L., Sala, M., Llovet, J.M., Focus on hepatocellular carcinoma. Cancer Cell 5:3 (2004), 215–219.
3. [3] Tung-Ping Poon, R., Fan, S.T., Wong, J., Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 232:1 (2000), 10–24.
4. [4] Aravalli, R.N., Steer, C.J., Cressman, E.N., Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:6 (2008), 2047–2063.
5. [5] Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414:6859 (2001), 105–111.
6. [6] Yang, Z.F., Ho, D.W., Ng, M.N., Lau, C.K., Yu, W.C., Ngai, P., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:2 (2008), 153–166.
7. [7] Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:3 (2009), 1012–1024.
8. [8] Jordan, C.T., Guzman, M.L., Noble, M., Cancer stem cells. N. Engl. J. Med. 355:12 (2006), 1253–1261.
9. [9] Ma, S., Chan, K.W., Hu, L., Lee, T.K., Wo, J.Y., Ng, I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:7 (2007), 2542–2556.
10. [10] Lee, T.K., Castilho, A., Cheung, V.C., Tang, K.H., Ma, S., Ng, I.O., CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9:1 (2011), 50–63.
11. [11] Yang, W., Wang, C., Lin, Y., Liu, Q., Yu, L.X., Tang, L., et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J. Hepatol. 57:3 (2012), 613–620.
12. [12] Diehn, M., Majeti, R., Metastatic cancer stem cells: an opportunity for improving cancer treatment?. Cell Stem Cell 6:6 (2010), 502–503.
13. [13] Warburg, O., On respiratory impairment in cancer cells. Science 124:3215 (1956), 269–270.
14. [14] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:5930 (2009), 1029–1033.
15. [15] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
16. [16] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:2 (2011), 85–95.
17. [17] Hsu, P.P., Sabatini, D.M., Cancer cell metabolism: warburg and beyond. Cell 134:5 (2008), 703–707.
18. [18] Magee, J.A., Piskounova, E., Morrison, S.J., Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:3 (2012), 283–296.
19. [19] Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69:11 (2009), 4918–4925.
20. [20] Gullino, P.M., Grantham, F.H., Courtney, A.H., Losonczy, I., Relationship between oxygen and glucose consumption by transplanted tumors in vivo. Cancer Res. 27:6 (1967), 1041–1052.
21. [21] Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15:6 (2009), 501–513.
22. [22] Wang, Y., Liu, Y., Malek, S.N., Zheng, P., Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8:4 (2011), 399–411.
23. [23] Flavahan, W.A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 16:10 (2013), 1373–1382.
24. [24] Wang, M.D., Wu, H., Fu, G.B., Zhang, H.L., Zhou, X., Tang, L., et al. Acetyl-CoA carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology, 2015.
25. [25] Urasaki, Y., Heath, L., Xu, C.W., Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors. PloS one, 7(5), 2012 e36775.
26. [26] Dwarakanath, B.S., Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res. Ther. 5 Suppl:1 (2009), S27–S31.
27. [27] Bhardwaj, R., Sharma, P.K., Jadon, S.S., Varshney, R., A combination of 2-deoxy-D-glucose and 6-aminonicotinamide induces oxidative stress mediated selective radiosensitization of malignant cells via mitochondrial dysfunction. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 32:5 (2011), 951–964.
28. [28] Yoshioka, K., Takahashi, H., Homma, T., Saito, M., Oh, K.B., Nemoto, Y., et al. A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. Biochim. Biophys. Acta 1289:1 (1996), 5–9.
29. [29] Macheda, M.L., Rogers, S., Best, J.D., Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 202:3 (2005), 654–662.
30. [30] Kumar, S.M., Liu, S., Lu, H., Zhang, H., Zhang, P.J., Gimotty, P.A., et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 31:47 (2012), 4898–4911.
31. [31] Zhu, P., Wang, Y., He, L., Huang, G., Du, Y., Zhang, G., et al. ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J. Clin. Invest. 125:10 (2015), 3795–3808.
32. [32] Wu, C.H., Ho, Y.S., Tsai, C.Y., Wang, Y.J., Tseng, H., Wei, P.L., et al. In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int. J. Cancer. J. Int. du Cancer 124:9 (2009), 2210–2219.
33. [33] Tomioka, S., Water transport by glucose transporter type 3 expressed in Xenopus oocytes. Neuroreport 23:1 (2012), 21–25.
34. [34] Boroughs, L.K., DeBerardinis, R.J., Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17:4 (2015), 351–359.
35. [35] Vazquez, F., Lim, J.H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., et al. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23:3 (2013), 287–301.
36. [36] Son, J., Lyssiotis, C.A., Ying, H., Wang, X., Hua, S., Ligorio, M., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:7443 (2013), 101–105.
37. [37] Carracedo, A., Cantley, L.C., Pandolfi, P.P., Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13:4 (2013), 227–232.
38. [38] De Luca, A., Fiorillo, M., Peiris-Pages, M., Ozsvari, B., Smith, D.L., Sanchez-Alvarez, R., et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 6:17 (2015), 14777–14795.
39. [39] Pang, R.W., Poon, R.T., From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 1:72 Suppl (2007), 30–44.
40. [40] Bu, L.L., Zhao, Z.L., Liu, J.F., Ma, S.R., Huang, C.F., Liu, B., et al. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell. Oncotarget 6:39 (2015), 41944–41958.
41. [41] Zhou, X., Ren, Y., Liu, A., Jin, R., Jiang, Q., Huang, Y., et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci. Rep., 4, 2014, 7461.
42. [42] Yuan, Z.L., Guan, Y.J., Wang, L., Wei, W., Kane, A.B., Chin, Y.E., Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol. Cell Biol. 24:21 (2004), 9390–9400.
43. [43] Fernandez, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., Bosch, J., Angiogenesis in liver disease. J. Hepatol. 50:3 (2009), 604–620.
44. [44] Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:4 (2008), 378–390.
45. [45] Gusani, N.J., Jiang, Y., Kimchi, E.T., Staveley-O'Carroll, K.F., Cheng, H., Ajani, J.A., New pharmacological developments in the treatment of hepatocellular cancer. Drugs 69:18 (2009), 2533–2540.
46. [46] Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 5:4 (2005), 275–284.
47. [47] Singh, A., Settleman, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:34 (2010), 4741–4751.
48. [48] Vlashi, E., Lagadec, C., Vergnes, L., Matsutani, T., Masui, K., Poulou, M., et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl. Acad. Sci. U. S. A. 108:38 (2011), 16062–16067.
49. [49] Lagadinou, E.D., Sach, A., Callahan, K., Rossi, R.M., Neering, S.J., Minhajuddin, M., et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12:3 (2013), 329–341.
50. [50] Palorini, R., Votta, G., Balestrieri, C., Monestiroli, A., Olivieri, S., Vento, R., et al. Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J. Cell Biochem. 115:2 (2014), 368–379.
51. [51] Liu, P.P., Liao, J., Tang, Z.J., Wu, W.J., Yang, J., Zeng, Z.L., et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 21:1 (2014), 124–135.
52. [52] Turkson, J., Jove, R., STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:56 (2000), 6613–6626.
53. [53] Tang, Y., Kitisin, K., Jogunoori, W., Li, C., Deng, C.X., Mueller, S.C., et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. U. S. A. 105:7 (2008), 2445–2450.
54. [54] Won, C., Kim, B.H., Yi, E.H., Choi, K.J., Kim, E.K., Jeong, J.M., et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 62:4 (2015), 1160–1173.
55. [55] Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:1 (2009), 25–34.
56. [56] Dalerba, P., Cho, R.W., Clarke, M.F., Cancer stem cells: models and concepts. Annu. Rev. Med. 58 (2007), 267–284.
57. [57] Guan, D.X., Shi, J., Zhang, Y., Zhao, J.S., Long, L.Y., Chen, T.W., et al. Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology 62:6 (2015), 1791–1803.